Leverage Noninvasive Transcutaneous Vagus Nerve Stimulation to Reduce Suicidal Behaviors in Vulnerable Adolescents

Suicidal Ideation Clinical Trial

Official title:

Leveraging Noninvasive Transcutaneous Vagus Nerve Stimulation and Smartphone Technology to Reduce Suicidal Behaviors and Suicide Among Highly Vulnerable Adolescents

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05602779
• Other study ID #: 22-08-7372
• Status: Recruiting
• Phase: N/A
• Start date: October 8, 2023
• Est. completion date: September 30, 2027

Study information

• Verified date: November 2023
• Source: University of Notre Dame
• Contact: Cheryl Lee, MS
• Phone: 574-631-5097
• Email: clee21[@]nd.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Suicidal thoughts, suicide attempts, and suicide are increasingly common in adolescence.

Current face-to-face prevention approaches are of limited effectiveness, rely on extensive resources, and are at odds with adolescents' digital preferences. We will evaluate two unconventional but promising interventions delivered to 13- to 17-year-olds: transcutaneous vagus nerve stimulation to target emotion dysregulation, and a peer-support smartphone app to combat social isolation. If effective, these digitally-delivered interventions could reach far more adolescents at far lower cost than current approaches.

Description:

Over the past two decades, suicide rates have increased nearly 35% in the U.S., with upward trends in nearly all demographic groups. Further increases have occurred since the COVID-19 pandemic began. Despite ambitious goals for reducing suicides and significant federal and private investment, suicide rates continue to rise unabated. To date, the predominant approach to mitigating suicide risk in the U.S. is secondary prevention. Typically, these programs identify risk of recurrence among those who have already attempted suicide at least once. Although secondary prevention is crucial, the majority of deaths by suicide occur on first attempt. Thus, targeted primary prevention earlier in development is essential. Most current primary prevention programs are intensive, expensive, and delivered by highly trained mental health providers, who are in short supply. Traditional face-to-face therapy is also unavailable to many who live in underserved communities, and disliked by adolescents, who much prefer digital delivery on their devices. This high-risk, high-reward proposal addresses these limitations and needs. We use an experimental therapeutics approach to evaluate the independent and combined efficacies of two unconventional but scalable interventions: transcutaneous vagus nerve stimulation (tVNS) to target emotion dysregulation, and a peer-support smartphone app to combat social isolation. These low-cost interventions, which hold strong promise but have not been used before, can reach large numbers of adolescents, with much potential to reduce prospective suicide risk. We will enroll 212 adolescents, ages 13-17 years, who show elevations on at least two prominent risk factors for suicide (e.g., self-injury, maltreatment).

Using a 2 × 2 design, adolescents will be assigned randomly to receive 30 days of treatment with:

1. tVNS to target emotion dysregulation,

2. a peer-support phone app to target social isolation,

3. tVNS + a peer-support phone app, or

4. enhanced treatment as usual with monitoring and access to resources.

Intervention effects on mechanisms (emotion dysregulation, social isolation) proximal efficacy signals (e.g., physiological reactivity, self-harm) and target outcomes (suicidal ideation, suicidal behaviors) will be evaluated immediately post-intervention and at one-year follow-up. Treatment data will be monitored daily to fine-tune dosing of both interventions. This transformative and innovative proposal tests two novel, scalable preventive interventions designed to "meet adolescents where they are" by using digital technologies to address core mechanisms of suicide risk.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 212
• Est. completion date: September 30, 2027
• Est. primary completion date: April 15, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 13 Years to 17 Years

Eligibility

Inclusion Criteria:

• Aged between 13 and 17 years,

• Attend in person meetings in South Bend, IN or Rochester, NY. and,

Two of the following which will be scored during the phone screen:

• Engaged in non-suicidal self-harm 3 times in the past 6 months or more than 5 times in their life time, with one occurrence in the past year.

• Show high scores on emotional dysregulation

• Show high scores on social isolation

• Show high scores on impulsivity

• Show high scores on depression

• Engage in alcohol or other substance use

Exclusion Criteria:

• Parent reported autism or schizophrenia

• Implanted pacemaker or cardiac defibrillator, other implanted or metallic device

• Pregnant or breast feeding

• History of seizures or epilepsy

• TMJ Disorder

• Bells' Palsy

• Impaired cranial nerve function

• Facial Pain

Related Conditions & MeSH terms

• Self Harm
• Self-Injurious Behavior
• Suicidal Ideation

Intervention

Device:
• tVns Program
Participants will use the Neuvana Xen device 30 minutes a day for 3 days. The device delivers stimulation through the left ear via an ear bud. Participants can use the device at any time of day.

Other:
• Phone App Program
Participants will have access to a specially designed phone app in order to play a game designed for this study. Approximately half of the participants will be able to connect with a fellow participant who is matched as their peer for social support.

Combination Product:
• tVNS and Phone App Program
Participants will have both the Neuvana Xen Device and the full version of our program's phone app. They will use the device and full app access for 30 days.

Other:
• Enhanced Treatment as Usual
Participants will have access to our program's phone app so the can play the game and will be called weekly to complete risk assessments.

Locations

Country	Name	City	State
United States	University of Notre Dame	South Bend	Indiana

Sponsors (2)

Lead Sponsor	Collaborator
University of Notre Dame	University of Rochester

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in Non-Suicidal Self Injury Behaviors at 30 Days	Teens will be assessed at the baseline lab visit for emotion regulation and self-harm through questions on the Qualtrics survey (measures are Difficulties in Emotion Regulation Scale and the Youth Self Report). They will also complete a face-to-face interview with a trained staff member to assess their level of non-suicidal self-injury, suicide ideation, and suicide attempts. In addition, we will collect measures of psychophysiological reactivity (heart rate variability, cardiac pre-ejection period) to emotional challenge.; All participants will complete the same tasks at subsequent visits (post-treatment, on-year follow-up) and it is hoped that teens who have used the tVNS device for the 30-day intervention period will show improved responses. For the rate of change, we will use percentile ranking vis-a-vis national norms.	30 Days
Primary	Improved Reports of Social Isolation and Loneliness	Each participating teen will complete questions regarding feelings of loneliness and social isolation on the Qualtrics survey while in the lab at each visit. We are using the 8-item UCLA loneliness scale to measure this in each teen.; Some teens will be assigned to using the peer support phone app where they will be matched with another teen in this study. They will play a cooperative game with each other, and be able to text and share thoughts, feelings, etc. with each other. This app will hopefully improve teen's self-reported feelings of isolation and loneliness.; For the rate of change, we will use percentile ranking vis-a-vis national norms.	30 Days
Primary	Improved Results from Participant's Typical Treatment	Teens who are not placed in one of the active intervention groups will still be able to access our phone app which allows them to play a non-cooperative game on their own, and they are able to text with our team members during regular business hours. The added support will hopefully help their current treatment plan to improve their thoughts and behaviors in regard to suicidal ideation and self-harm.; For the rate of change, we will use percentile ranking vis-a-vis national norms.	30 Days
Secondary	Adherence to tVNS and Phone App intervention from Baseline to 30 days.	Using data from the Xen device and the phone app, we will be able to determine the number of occurances the device and app were accessed, as well as for how much time each was actively used. Participants will also report on acceptability, obtrusiveness, and favorability of both the device and the phone app.	30 Days